Vaccination provides superior in vivo recall capacity of SARS-CoV-2-specific memory CD8 T cells

Cell Rep. 2023 Apr 25;42(4):112395. doi: 10.1016/j.celrep.2023.112395. Epub 2023 Apr 4.

Abstract

Memory CD8 T cells play an important role in the protection against breakthrough infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whether the route of antigen exposure impacts these cells at a functional level is incompletely characterized. Here, we compare the memory CD8 T cell response against a common SARS-CoV-2 epitope after vaccination, infection, or both. CD8 T cells demonstrate comparable functional capacity when restimulated directly ex vivo, independent of the antigenic history. However, analysis of T cell receptor usage shows that vaccination results in a narrower scope than infection alone or in combination with vaccination. Importantly, in an in vivo recall model, memory CD8 T cells from infected individuals show equal proliferation but secrete less tumor necrosis factor (TNF) compared with those from vaccinated people. This difference is negated when infected individuals have also been vaccinated. Our findings shed more light on the differences in susceptibility to re-infection after different routes of SARS-CoV-2 antigen exposure.

Keywords: CD8 T cells; COVID-19; CP: Immunology; SARS-CoV-2; antigen-specific T cells; clonal diversity; infection; influenza; memory cells; transcriptome; vaccination.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CD8-Positive T-Lymphocytes
  • COVID-19*
  • Humans
  • SARS-CoV-2
  • Tumor Necrosis Factor-alpha
  • Vaccination

Substances

  • Tumor Necrosis Factor-alpha